Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Re mass spectrometry
relevant scancell links
https://www.scancell.co.uk/citrullinated-glucose-regulated-protein-78-is-a-candidate-target-for-melanoma-immunotherapy
“This peptide is detected by mass spectrometry”
Results: We show the identification CD4 T cell responses to one citrullinated GRP78 epitope that are restricted through HLA DP*0401 and HLA-DR*0101 alleles. This peptide is detected by mass spectrometry in B16 melanoma grown in vivo and citrulline specific CD4 responses to two peptides spanning this epitope mediate efficient therapy of established B16 melanoma tumours in HHDII/DP4 (p
Cancer vaccine , how far have we come from curing cancer ,
written by Rahul Chowdhury and Lindy Durrant
February 2019
https://www.researchgate.net/publication/336421539_Cancer_vaccine_how_far_are_we_from_curing_cancer
Cites Catherine Wu .
Would we all agree Scancell have made gigantic steps since then ?
Looks like star price is improving
https://www.local.gov.uk/sites/default/files/documents/34.2_Probity_in_Planning_04.pdf
Morning all in all , I believe the scancell team are doing an excellent job at establishing an experiences commercial team around their groundbreaking science . the new auditors are another wheel in the cog . The well documentented delays were forgivable if it happened once , however the second delay . was totally unprofessional and must have placed a strain on an important relationship . So the change was I believe necessary .
we know the above fiasco resulted in a share price decline . that's bumped around 11-12p with an astonishing spread of 14 % what the views on this ?
BOJO excellent post . The Scancell team and Lindy Durrant are showing no signs of being wall flowers in the pharma stakes . Hopefully the dance card will be full of potential partners
Best of luck to one and all . Especially to all the patients x
Yes your correct Chester fast track approval we hope by the FDA . Am I correct in thinking Lindy said trials are going to be conducted in USA . Hopefully the recruitment in the trials will be speeding up with the melanoma focus conference . Good luck to one and all
Markus2 gave heads up on this from other board . here is the link
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Thinking aloud I wonder if Merck and Moderna will carry on with the trial because of the following :
A very expensive trial ? ! Very complicated!
The genetic aberrations of each individual patient with cancer is different, which creates a challenge for the development of therapeutic cancer vaccines. One approach is to characterize the tumor from each individual, so that the vaccine can be tailored precisely for that person in order to be better targeted. This approach is difficult to scale up, takes more time and results in higher cost. The alternative is to develop off-the-shelf vaccines, but the challenge is how to make them sufficiently targeted and effective across a wide range of individuals. The pros and cons of these two approaches will be discussed"
Good point rat please find useful links below
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-SCIB1-pembrolizumab-advanced-melanoma#undefined
The above link is now on the cancer research. Page in a user friendly format
Hopefully at the up and coming melanoma conference for patients and clinicians . the trial update given by Sarah Danson will help recruit patients onto the trials .
https://melanomafocus.org/support/melanoma-patient-conference/
From other board
marcusl2: Therapeutic Cancer Vaccines
Immunological Advances for Cancer Treatment
23 - 24 APRIL 2024 ALL TIMES BST
Scancell, Moderna and Ultimovacs.
Gritstone,Adaptimmune.
Companies at the cutting edge I would argue.
https://www.immuno-oncologyeurope.com/cancer-vaccines#LindyDurrant
14:45
Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination
Lindy Durrant, BSc, PhD, Professor, CEO, Scancell Ltd.
SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial
Breakout Discussion with Afternoon Refreshments
15:15
Breakout Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Breakout Discussions page on the conference website for a complete listing of topics and descriptions.
BREAKOUT DISCUSSION:
TOPIC: The Pros and Cons of Personalized vs Off-the-Shelf Cancer Vaccines
Jonathan Kwok, CEO, Infinitopes
The genetic aberrations of each individual patient with cancer is different, which creates a challenge for the development of therapeutic cancer vaccines. One approach is to characterize the tumor from each individual, so that the vaccine can be tailored precisely for that person in order to be better targeted. This approach is difficult to scale up, takes more time and results in higher cost. The alternative is to develop off-the-shelf vaccines, but the challenge is how to make them sufficiently targeted and effective across a wide range of individuals. The pros and cons of these two approaches will be discussed
Https://vimeo.com/907889586/5d861ac47d
For those who wish to listen again for their own clarity on their investment.
Believe the recent grant given to Nottingham was a considerable sum£ 12.3 in Glyco cell engineering.
Yes I do believe LD did say they believed they were the only ones in this Glyco man space at the AGM 2022 ?
Clearly their is confidence and affirmation that this is an exciting area to be in .
Scancell have the patents in place
The recent RNS releases show determination, resilience and all with beefed up management
Come on Scancell looking forward to hearing more on trial results
All the best to one and all
DYOR
Read my recent posts on Nottingham University, getting a £12.3 million grant on glycan cell engineering?
On linked in today February 11th marks the International Day of Women and Girls in Science. Coined by the United Nations, this day is marked to recognise #diversity in research, expand the pool of talented researchers and bring in fresh perspectives, talent and creativity.
Scancell Ltd is an ambitious #cancer focussed biotech founded by pioneering scientist Lindy Durrant. Today, we shine a light on her dedication to revolutionize #cancer therapy though her innovative research, as well as all the scientists for their continued contribution to furthering Scancell's clinical development and growing success.
💡 Read the posts to see who and what inspired some of our scientists to pursue a career in research.
📰 ICYMI – Last year, Lindy Durrant was profiled in the Guardian, read why: https://lnkd.in/gUBjzDmF
#InternationalDayOfWomenAndGirlsInScience #immunotherapy #vaccines #immunooncology #cancerresearch #biotech #immunology
I think someone posted this link before , however find recent version
Trials requested to be added to Thames Valley ARIA (if not on this list a request has not been received)
Version on Aria 8/02/24
https://thamesvalleycanceralliance.nhs.uk/wp-content/uploads/2024/02/Trials-Aria-February-a-2024.pdf
Bottom pf page 12
Skin SCRIB1-002. Trial version 5 , amendment received 6 awaiting R&D approval
Exactly the S
Glycans have a huge impact on biology, are integral to the way that our immune system interacts with pathogens, and ensure that many modern pharmaceuticals function properly. However, glycans are currently very difficult to study and manufacture and can be considered to be the “dark matter” of biology.
The GlycoCell Engineering Biology Mission Hub will bring together a range of experts from different fields to unlock the potential of glycans. This promises to accelerate vaccine discovery and production, generate new therapeutics and diagnostics, and dramatically reduce the production costs of advanced drugs.
GlycoCell will:
Unlock our ability to program glycan sugars, opening a world of research opportunities in biology and medical biotechnology.
Design, test and make many new therapeutics, diagnostics and vaccines against pathogens that impact human and animal health.
Enhance our epidemic preparedness.
Counteract antimicrobial resistance by developing vaccines against bacterial and fungal pathogens, reducing our reliance on antibiotics to combat these threats.
Develop the technology to move production of advanced drugs to microbial hosts, considerably reducing their cost thanks to scalable production.
Build and deploy GlycoForge, a specialist automated facility, as a UK national asset that will routinely develop vaccines, diagnostics and therapeutics, and will be ready to deliver a 100-day rapid response to new pandemic threats.
Train the current generation and develop future leaders in Engineering Biology for academia, industry and the public sector.
We are delighted to receive this significant investment from DSIT and UKRI to take the GlycoCell Hub forward. It will make a leading, transformative contribution to bringing about a healthier, more sustainable, equitable and prosperous future.”
Dr John Heap from the School of Life Sciences at the University of Nottingham is the Principal Investigator and Co-Director of the Hub, working with a team of colleagues.
Professor Brendan Wren from the LSHTM is Co-Director of the Hub. He said: “Glycans or sugars play key roles in both fundamental biology and biotechnology. The GlycoCell consortium will exploit novel Engineering Biology approaches to produce more effective glycan-based therapeutics, diagnostics and vaccines.”
Announcing the funding the Science, Research and Innovation Minister, Andrew Griffith, said: “Engineering biology has the power to transform our health and environment, from developing life-saving medicines to protecting our environment and food supply and beyond.
“Our latest £100m investment through the UKRI Technology Missions Fund will unlock projects as diverse as developing vaccines, as I saw Nottingham this week, preventing food waste through disease resistant crops, reducing plastic pollution, and even driving efforts to treat snakebites.
“With new Hubs and Mission Awards spread across the country, from Edinburgh to Por
GlycoCell Engineering Biology Mission Hub: Transforming glycan biomanufacture for health
https://www.nottingham.ac.uk/news/glycocell-engineering-biology-mission-hub
The University of Nottingham will lead a national hub that will develop vaccines, diagnostics and therapeutics, benefiting millions of people worldwide, thanks to funding from UK Research and Innovation (UKRI).
The GlycoCell Engineering Biology Mission Hub will receive £12.3 million in funding as part of an overall investment of £100m from UKRI’s Technology Missions Fund and UKRI and BBSRC’s core budgets.
Just wondering what the thoughts are on Toxicity risks of mRNA formulated with lipid nanoparticles. The report is from Moderna Scientists
The following articles one behind a paywall
https://www.ntd.com/moderna-scientists-warn-mrna-vaccines-carry-toxicity-risks_970876.html
The technology used in Moderna’s COVID-19 vaccine carries toxicity risks, scientists with the company said in a new paper.
“A major challenge now is how to efficiently de-risk potential toxicities associated with mRNA technology,” the scientists wrote.
Authors of the paper include Eric Jacquinet and Dimitrios Bitounis, Moderna employees, and Maximillian Rogers, who was working at Moderna when the paper was being done.
The paper was published by Nature Reviews Drug Discovery on Jan. 23.
Moderna did not respond to a request for comment.
https://www.nature.com/articles/s41573-023-00859-3
“mRNA formulated with lipid nanoparticles is a transformative technology that has enabled the rapid development and administration of billions of coronavirus disease 2019 (COVID-19) vaccine doses worldwide. However, avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges”
KD all well and good. However as tax payers want to know what the contract is and for how much
Not remotely “ green eyed “ just want transparency
Don't feel entirely comfortable with the 10 year contract for "undisclosed sum"
6th of Feb 2023
https://goodlawproject.org/sunak-linked-hedge-fund-sees-pandemic-profits-soar-to-109m/
A hedge fund where the Prime Minister, Rishi Sunak, was a founding partner, has seen its profits more than double in a year. Annual reports published on Companies House reveal that Theleme Partners made £109m in the year up to 31 March 2022 – a £65m increase from the previous year.
Theleme is heavily invested in Covid vaccine manufacturers Moderna – which last month signed a 10-year partnership with the UK Government for an undisclosed sum.
It’s intrigue around this scientific vaccine space …Moderna modus operandi was personalised mRNA . EE indeed!
However with the recent press release, with comments from David Pinato . One can speculate?
I have sat on this link for a week or so , imagine content and website was produced before Moderna press release on off their shelf vaccine
Is Moderna ip ” in trouble ? “
Is BioNTech going to announce a contender
Chelsea good analogy! Or vinyl, Cassettes v DVD v iPod v streaming
( we know vinyl back in vogue )
Will be an interesting conference free to some . Clearly a lot going on
Good to see Kate Bingham on the agenda ?
Https://www.convenzis.co.uk/events/the-great-national-cancer-vaccine-summit
3 trial investigators are speaking check agenda
Christian Ottenmeiser
Heather shaw , and Sarah Danson